Angiomax adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Angiomax
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Product name as reported

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From February 2004 to November 2024, FDA received 1,484 adverse event reports that name Angiomax. The name is as reporters wrote it. In these reports the drug is a suspect or interacting product.

In the same period, 254 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 0 reports in the 12 months to June 2026 and 3 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Angiomax is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

No update is on record for this page. The record starts when FDA adds the reports of July to September 2026.

FDA received no report that names Angiomax in April to June 2026, in January to March 2026 or in April to June 2025.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 113 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 1,456 of the 1,484 reports (98.1%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 113 terms.

Reaction terms in the reports that name Angiomax, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 1,484 reports
Thrombosis in devicea blood clot in the device	199	13.4%
Coronary artery thrombosis	170	11.5%
Thrombosis	142	9.6%
Haemorrhagebleeding	120	8.1%
Coagulation time abnormal	114	7.7%
Stent occlusion	96	6.5%
Myocardial infarctionheart attack	94	6.3%
Chest pain	91	6.1%
Hypotensionlow blood pressure	87	5.9%
Procedural complication	63	4.2%
Off label useused for a purpose or in a way not on the label	60	4%
Cardiac arrestthe heart stopped	59	4%
Cerebrovascular accidentstroke	47	3.2%
International normalised ratio increasedblood clotting slower than intended (raised INR)	47	3.2%
Cardio-respiratory arrestthe heart and breathing stopped	46	3.1%
Haematomaa collection of blood under the skin or in tissue	46	3.1%
Coronary artery occlusion	45	3%
Acute myocardial infarction	43	2.9%
Drug ineffectivethe medicine did not work as expected	39	2.6%
Post procedural complicationa complication after a procedure	39	2.6%
Haemorrhage intracranial	38	2.6%
Retroperitoneal haemorrhage	36	2.4%
Haemoglobin decreasedlow haemoglobin	35	2.4%
Gastrointestinal haemorrhagebleeding in the stomach or bowel	33	2.2%
Dyspnoeashortness of breath	30	2%
Ventricular fibrillationa chaotic rhythm from the lower heart chambers	30	2%
Cardiac procedure complication	28	1.9%
Coronary artery perforation	28	1.9%
Bradycardiaslow heart rate	27	1.8%
Coronary artery dissection	27	1.8%
Cardiogenic shockshock from the heart failing to pump	26	1.8%
Coagulation time prolonged	26	1.8%
Electrocardiogram ST segment elevation	24	1.6%
Vascular stent thrombosis	24	1.6%
Deaththe patient died; cause not stated by this term	23	1.5%
Hypersensitivityan allergic-type reaction	23	1.5%
Overdosea dose above the recommended amount	23	1.5%
Post procedural haemorrhage	23	1.5%
Cerebral haemorrhage	22	1.5%
Vascular pseudoaneurysm	22	1.5%
Cardiac tamponade	21	1.4%
Haematocrit decreased	21	1.4%
Anaphylactic reactiona severe, sudden allergic reaction	19	1.3%
Coagulopathy	18	1.2%
Nauseafeeling sick	18	1.2%
Activated partial thromboplastin time prolonged	17	1.1%
Ventricular tachycardiaa fast rhythm from the lower heart chambers	17	1.1%
Device occlusionthe device blocked	16	1.1%
Headachehead pain	16	1.1%
Iatrogenic injury	16	1.1%

Download all 113 terms of Angiomax (CSV)

The counts add to more than 1,484 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Angiomax, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Other Serious (Important Medical Events)	Not serious
2004	109	96	18	21	52	2	33	13
2005	123	109	39	12	26	2	67	14
2006	148	135	28	24	42	3	79	13
2007	169	161	37	18	27	4	117	8
2008	198	198	54	25	24	3	145	0
2009	144	144	50	15	24	2	107	0
2010	152	151	61	18	36	7	119	1
2011	76	75	15	4	6	0	65	1
2012	64	64	24	27	10	1	45	0
2013	37	34	11	6	10	0	21	3
2014	39	39	16	3	3	0	19	0
2015	148	127	17	12	12	3	103	21
2016	17	15	3	3	2	1	11	2
2017	13	9	2	3	3	1	6	4
2018	3	3	0	2	2	0	3	0
2019	19	16	4	3	7	0	7	3
2020	10	9	8	0	0	0	6	1
2021	6	6	3	0	0	0	4	0
2022	3	1	1	0	1	0	0	2
2023	3	1	1	0	1	0	1	2
2024	3	3	0	1	2	0	2	0

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Angiomax, by the year in which FDA received them

Show the figures of the chart as a table

Reports that name Angiomax, by the year in which FDA received them
Year	Reports
2004	53
2005	110
2006	138
2007	157
2008	187
2009	191
2010	149
2011	135
2012	65
2013	41
2014	42
2015	141
2016	17
2017	12
2018	2
2019	19
2020	10
2021	6
2022	4
2023	2
2024	3

Reports that name Angiomax, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Angiomax
Age	Reports	Share
Under 2	7	0.5%
2 to 11	8	0.5%
12 to 17	1	0.1%
18 to 44	41	2.8%
45 to 64	368	24.8%
65 to 74	221	14.9%
75 and over	226	15.2%
Age not given	612	41.2%

Sex of the patient in the reports that name Angiomax
Sex	Reports	Share
Female	477	32.1%
Male	636	42.9%
Unknown or not given	371	25%

Type of reporter in the reports that name Angiomax
Reporter	Reports	Share
Physician	695	46.8%
Pharmacist	197	13.3%
Other health professional	339	22.8%
Lawyer	6	0.4%
Consumer or non-health professional	29	2%
Not given	218	14.7%

Age and sex are as the report gives them. The reporter is the primary source in the report. 81.4% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Angiomax record
Indication as recorded (MedDRA)	Reports	Share
Percutaneous coronary intervention	666	44.9%
Anticoagulant therapy	63	4.2%
Coronary angioplasty	36	2.4%
Heparin-induced thrombocytopenia	23	1.5%
Acute coronary syndrome	21	1.4%
Catheterisation cardiac	21	1.4%

The reporter fills in the indication, and the field is often empty. Each share is of all 1,484 reports.

Pages near this one

Angeliq next in the A to Z list
Anidulafungin next in the A to Z list
Androgel 1% next in the A to Z list
Anifrolumab next in the A to Z list
Androgel 1 62% next in the A to Z list
Annovera next in the A to Z list
Androgel next in the A to Z list
Anoro Ellipta next in the A to Z list
Androderm next in the A to Z list
Anti Thymocyte Globulin next in the A to Z list
Androcur next in the A to Z list
Anti-inhibitor coagulant complex next in the A to Z list

These links are for navigation. No count selected them.

Official pages

DailyMed labels for AngiomaxThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Angiomax: adverse event reports that FDA received. https://reportedreactions.com/drug/angiomax/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Angiomax as a suspect or interacting product. The 254 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Angiomax was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Angiomax?

No. It is a count of what people reported to FDA: 1,484 reports from February 2004 to November 2024. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Physician (46.8%), other health professional (22.8%) and pharmacist (13.3%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page